Adagio Therapeutics, Inc. (ADGI) stock plunged 68.45% in the current-market trading session at the price of $10.81 despite no fundamental reason.  

ADGI is a clinical-stage biopharmaceutical firm. The company develops and commercializes antibody-based solutions to treat contagious diseases, including influenza and COVID-19.  

ADGI Published Data About SARS-CoV-2 Antibody, ADG20 

On 29th November 2021, ADGI published data regarding the potential of its SARS-CoV-2 antibody, ADG20, in the fight against the Omicron variant. ADG20 is an investigational monoclonal antibody product candidate developed to boost neutralizing action against SARS-CoV-2. The single dose of antibody provides potent prevention and treatment against COVID-19 with a potential duration of defense for up to a year. Given the potential health concerns resulting from Omicron, ADGI is launching several activities to support ADG20’s utility in handling this newly emerged variant. 

Management Comments   

Co-founder and chief scientific officer of ADGI, Laura Walker, remarked that unlike other antibodies listed under EUA, ADG20 had shown positive results to address a highly conserved epitope. ADG20 will retain protection against Omicron due to the immunorecessive nature of the epitope. ADG20 had devised to provide broad neutralizing activity against SARS-CoV-2 and future viruses with pandemic potential. 

Co-founder and chief executive officer of ADGI, Tillman Gerngross, commented that ADG20 had developed to combine capacity, potency, and duration of defense against Covid-19 for up to one year. The virus would continue to emerge that render earlier therapies and vaccines outdated. The international clinical trials are progressing with potential EUA submissions for the prevention and treatment against SARS-CoV-2. They will keep collaborating with the FDA and other regulatory and governmental bodies to discuss novel therapeutic solutions to fight the pandemic. 

ADGI Expanded Management Team to Support ADG20 

On 22nd November 2021, ADGI reported the appointment of Jill Andersen as its chief legal officer. He has near 20 years of legal and leadership experience in the pharmaceutical industry. Additionally, Redonda Miller, a professional corporate director, had joined the company’s board of directors. He has worked as the CEO of several consumer product companies and the president of The Johns Hopkins Hospital.  


Please enter your comment!
Please enter your name here